This balanced cannabinoid formulation delivers 10 mg each of THC, CBD and CBG per unit, supported by a 2.0% total terpene profile. Notable constituents include Limonene (0.60% w/w), beta-Caryophyllene (0.60% w/w) and Pinene (0.80% w/w), producing a consistent sativa-leaning chemotype intended for daytime or early-evening therapeutic contexts.

Southern Sky Sativa Pastilles are manufactured in small batches using a gelatin base, MCT oil as the carrier, and CO₂-extracted cannabinoids. All pastilles are produced in Australia using Australian inputs, with formulation controls designed to maintain consistent flavour, texture, cannabinoid distribution, and terpene retention throughout the batch.

Anecdotally, patients describe an uplifting and clear-headed onset, often noting improved focus, steadier mood, and a calm but functional effect profile. These pastilles are commonly selected by prescribers for patients presenting with mood disorders, stress-related conditions, PTSD, chronic pain or appetite difficulties, with reports of balanced cognitive effects and a gentle stabilising influence.

As with all oral cannabinoid formulations, consideration of slower onset and longer duration may be helpful when initiating therapy. Conservative titration is generally recommended, especially in patients unfamiliar with multi-cannabinoid products.